ArticleFrontiers in oncology2026
Ultrasound-based radiomics and habitat analysis for noninvasive assessment of Ki-67 overexpression in breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate preoperative assessment of Ki-67 proliferation index remains a clinical challenge in breast cancer management. Conventional ultrasound radiomics often fails to fully capture intratumoral heterogeneity, suffers from overfitting, and includes redundant features that limit generalizability. Methods: In this retrospective study, we analyzed preoperative ultrasound images and immunohistochemical results from 288 women with pathologically confirmed breast cancer. We extracted both conventional radiomic features and intratumoral habitat features, computed risk scores, and integrated them with clinicopathological variables (e.g., progesterone receptor status, lymph node involvement) to construct a nomogram. Model performance was assessed by area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). Results: The Clinics_Habitat_Radiomics model achieved AUCs of 0.877 (95% CI: 0.826-0.929) in the training cohort and in the validation cohort, the model achieved an AUC of 0.830, with a sensitivity of 60.3% and specificity of 91.7%, significantly outperforming other models. Calibration curves indicated close agreement between predicted probabilities and observed outcomes (Hosmer-Lemeshow test: Conclusions: The integration of habitat analysis with ultrasound-based radiomics enables the development of a nomogram that synergistically incorporates multimodal imaging features and clinicopathological parameters, offering a non-invasive predictive tool for Ki-67 expression in breast cancer. This model not only enhances the precision of tumor biology assessment but also provides actionable insights for optimizing therapeutic regimens, monitoring treatment responses, and stratifying prognostic risks, thereby bridging the gap between radiomic diagnostics and personalized oncology care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.